- Home
- PETZ vs ATHE Comparison
PETZ vs ATHE Comparison
Compare PETZ & ATHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- ATHE
- Stock Information
- Founded
- PETZ 2002
- ATHE 1997
- Country
- PETZ China
- ATHE Australia
- Employees
- PETZ N/A
- ATHE N/A
- Industry
- PETZ Steel/Iron Ore
- ATHE Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- ATHE Health Care
- Exchange
- PETZ Nasdaq
- ATHE Nasdaq
- Market Cap
- PETZ 13.1M
- ATHE 11.1M
- IPO Year
- PETZ 2017
- ATHE N/A
- Fundamental
- Price
- PETZ $1.16
- ATHE $1.33
- Analyst Decision
- PETZ
- ATHE Buy
- Analyst Count
- PETZ 0
- ATHE 1
- Target Price
- PETZ N/A
- ATHE $4.00
- AVG Volume (30 Days)
- PETZ 9.7K
- ATHE 10.3K
- Earning Date
- PETZ 10-29-2024
- ATHE 10-02-2024
- Dividend Yield
- PETZ N/A
- ATHE N/A
- EPS Growth
- PETZ N/A
- ATHE N/A
- EPS
- PETZ N/A
- ATHE N/A
- Revenue
- PETZ $3,175,809.00
- ATHE $2,502,579.00
- Revenue This Year
- PETZ N/A
- ATHE N/A
- Revenue Next Year
- PETZ N/A
- ATHE N/A
- P/E Ratio
- PETZ N/A
- ATHE N/A
- Revenue Growth
- PETZ 2.49
- ATHE N/A
- 52 Week Low
- PETZ $0.89
- ATHE $1.01
- 52 Week High
- PETZ $1.74
- ATHE $5.41
- Technical
- Relative Strength Index (RSI)
- PETZ 45.74
- ATHE 41.96
- Support Level
- PETZ $1.10
- ATHE $1.25
- Resistance Level
- PETZ $1.21
- ATHE $1.34
- Average True Range (ATR)
- PETZ 0.06
- ATHE 0.09
- MACD
- PETZ -0.00
- ATHE -0.00
- Stochastic Oscillator
- PETZ 31.58
- ATHE 8.33
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About ATHE Alterity Therapeutics Limited
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.